MX2022001535A - Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion. - Google Patents

Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion.

Info

Publication number
MX2022001535A
MX2022001535A MX2022001535A MX2022001535A MX2022001535A MX 2022001535 A MX2022001535 A MX 2022001535A MX 2022001535 A MX2022001535 A MX 2022001535A MX 2022001535 A MX2022001535 A MX 2022001535A MX 2022001535 A MX2022001535 A MX 2022001535A
Authority
MX
Mexico
Prior art keywords
sepiapterin
radiation exposure
metabolites
treat radiation
treat
Prior art date
Application number
MX2022001535A
Other languages
English (en)
Spanish (es)
Inventor
Neil Smith
Eleonora Mezzaroma
Christopher Rabender
Ross Mikkelsen
Vasily Yakovlev
Original Assignee
Ptc Therapeutics Mp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc filed Critical Ptc Therapeutics Mp Inc
Publication of MX2022001535A publication Critical patent/MX2022001535A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MX2022001535A 2019-08-05 2020-08-05 Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion. MX2022001535A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962882937P 2019-08-05 2019-08-05
PCT/US2020/045026 WO2021026247A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Publications (1)

Publication Number Publication Date
MX2022001535A true MX2022001535A (es) 2022-03-04

Family

ID=72148243

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001535A MX2022001535A (es) 2019-08-05 2020-08-05 Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion.

Country Status (21)

Country Link
US (1) US12667569B2 (cg-RX-API-DMAC10.html)
EP (2) EP4454712A3 (cg-RX-API-DMAC10.html)
JP (2) JP7642611B2 (cg-RX-API-DMAC10.html)
CN (2) CN119837879A (cg-RX-API-DMAC10.html)
AU (1) AU2020324435B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022002029A2 (cg-RX-API-DMAC10.html)
CA (1) CA3146477A1 (cg-RX-API-DMAC10.html)
DK (1) DK4009978T3 (cg-RX-API-DMAC10.html)
ES (1) ES2994060T3 (cg-RX-API-DMAC10.html)
FI (1) FI4009978T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20241653T1 (cg-RX-API-DMAC10.html)
HU (1) HUE069012T2 (cg-RX-API-DMAC10.html)
IL (1) IL290321B2 (cg-RX-API-DMAC10.html)
LT (1) LT4009978T (cg-RX-API-DMAC10.html)
MX (1) MX2022001535A (cg-RX-API-DMAC10.html)
PL (1) PL4009978T3 (cg-RX-API-DMAC10.html)
PT (1) PT4009978T (cg-RX-API-DMAC10.html)
RS (1) RS66096B1 (cg-RX-API-DMAC10.html)
SI (1) SI4009978T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202500089T1 (cg-RX-API-DMAC10.html)
WO (1) WO2021026247A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
WO2005048926A2 (en) * 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
CA2545968C (en) 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
CN101132776A (zh) 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006118322A1 (en) 2005-04-28 2006-11-09 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
TWI359019B (en) * 2006-08-14 2012-03-01 Merck Eprova Ag Use of folates for the prevention and treatment of
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
KR20160065998A (ko) 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
JP5066756B2 (ja) 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
CA2828685C (en) 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
JP6084967B2 (ja) 2012-05-07 2017-02-22 白鳥製薬株式会社 セピアプテリン及びテトラヒドロラクトイルプテリンの製造法
JP2016530333A (ja) * 2013-09-13 2016-09-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 放射線の影響から防護するため及び放射線の影響を緩和するための組成物の調製及び使用
CN114306208A (zh) * 2014-10-02 2022-04-12 西托索尔本茨公司 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗的用途
WO2018019931A1 (en) 2016-07-29 2018-02-01 Dipharma S.A. Pharmaceutical composition kit comprising sapropterin dihydrochloride
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) * 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
CN110354133A (zh) * 2019-08-26 2019-10-22 鞍山市肿瘤医院 四氢生物蝶呤的应用及药物
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
CA3165636A1 (en) 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin
IL305037A (en) 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
AR127191A1 (es) 2021-09-29 2023-12-27 Ptc Therapeutics Inc Composición farmacéutica de sepiapterina

Also Published As

Publication number Publication date
EP4009978A1 (en) 2022-06-15
EP4454712A2 (en) 2024-10-30
SMT202500089T1 (it) 2025-03-12
ES2994060T3 (en) 2025-01-16
CA3146477A1 (en) 2021-02-11
IL290321B2 (en) 2026-08-01
US12667569B2 (en) 2026-06-30
US20220273661A1 (en) 2022-09-01
EP4454712A3 (en) 2025-01-01
CN114555090A (zh) 2022-05-27
IL290321A (en) 2022-04-01
PT4009978T (pt) 2024-11-05
HRP20241653T1 (hr) 2025-04-25
PL4009978T3 (pl) 2025-02-24
JP7642611B2 (ja) 2025-03-10
AU2020324435B2 (en) 2026-03-19
LT4009978T (lt) 2024-11-25
RS66096B1 (sr) 2024-11-29
JP2022543655A (ja) 2022-10-13
BR112022002029A2 (pt) 2022-06-07
FI4009978T3 (fi) 2024-11-01
IL290321B1 (en) 2026-04-01
CN119837879A (zh) 2025-04-18
EP4009978B1 (en) 2024-09-25
AU2020324435A1 (en) 2022-02-24
HUE069012T2 (hu) 2025-02-28
CN114555090B (zh) 2024-12-17
SI4009978T1 (sl) 2025-03-31
WO2021026247A1 (en) 2021-02-11
JP2025098011A (ja) 2025-07-01
DK4009978T3 (da) 2024-10-14

Similar Documents

Publication Publication Date Title
BR112022002029A2 (pt) Uso de sepiapterina e seus metabólitos para tratar exposição à radiação
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
CO2021013339A2 (es) Degradadores de stat y usos de los mismos
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
MX2019013858A (es) Inhibidores de kras g12c y metodos para su uso.
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
CY1125116T1 (el) Ενας αναστολεας βτκ για χρηση στη θεραπεια του καρκινου
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CR20190376A (es) Formulaciones de anticuerpos de her2 subcutáneas
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
ECSP21021189A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
ECSP17059323A (es) Formulacion de combinacion de tesofensina y betabloqueante
CL2024000250A1 (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
MX2024003655A (es) Metodos para tratar cancer.
CL2020003118A1 (es) Régimen de dosificación para el tratamiento de trastornos relacionados con pi3k.
MX2021001612A (es) Compuestos utiles en terapia del vih.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
ECSP22043592A (es) Inhibidores de egfr alost?ricos y m?todos de uso de los mismos
CL2015002171A1 (es) Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble.
MX2021007177A (es) Formulacion de inhalacion de polvo seco y su uso para el tratamiento terapeutico de los pulmones.
BR112018009745A8 (pt) compostos heterocíclicos para o tratamento de doença